BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines internal R&D Expense ($M) ($M)
Form 10-Q / 10-K MD&A R&D Expense Summary Table
Latest, FY2025
1,287
Period ended Dec 31, 2025
Change on a year earlier
+5.1%
1,225 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Internal R&D Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,287 | +5.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 1,225 | +8.7% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 1,127 | +12.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1,003 | +28.2% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 783 | +38.3% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 566 | +43.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 394 | +207.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 128 | +241.3% | Form 10-K (filed 2019-02-28) ↗ |
| FY2017 | Dec 31, 2017 | 37.6 | 0.0% | Form 10-K (filed 2018-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 37.6 | – | Form 10-K (filed 2018-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Internal R&D Expense ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_internal
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.